ShockWave Medical
Market Cap
US$2.5b
Last Updated
2020/09/19 06:41 UTC
Data Sources
Company Financials +
Executive Summary
ShockWave Medical, Inc., a medical device company, develops and commercializes intravascular lithotripsy technology to treat calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases. More Details
Rewards
Risk Analysis
Currently unprofitable and not forecast to become profitable over the next 3 years
Snowflake Analysis
Excellent balance sheet with limited growth.
Similar Companies
Share Price & News
How has ShockWave Medical's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: SWAV's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
9.8%
SWAV
1.1%
US Medical Equipment
1.0%
US Market
1 Year Return
117.2%
SWAV
15.4%
US Medical Equipment
13.6%
US Market
Return vs Industry: SWAV exceeded the US Medical Equipment industry which returned 15.4% over the past year.
Return vs Market: SWAV exceeded the US Market which returned 13.6% over the past year.
Shareholder returns
| SWAV | Industry | Market | |
|---|---|---|---|
| 7 Day | 9.8% | 1.1% | 1.0% |
| 30 Day | 20.9% | 1.5% | -0.4% |
| 90 Day | 57.2% | 12.0% | 8.9% |
| 1 Year | 117.2%117.2% | 16.4%15.4% | 16.2%13.6% |
| 3 Year | n/a | 73.3%68.8% | 40.2%30.8% |
| 5 Year | n/a | 149.6%130.6% | 89.6%68.2% |
Price Volatility Vs. Market
How volatile is ShockWave Medical's share price compared to the market and industry in the last 5 years?
Simply Wall St News
5 months ago | Simply Wall St
ShockWave Medical (NASDAQ:SWAV) Shareholders Have Enjoyed A 22% Share Price Gain7 months ago | Simply Wall St
ShockWave Medical, Inc. Released Earnings Last Week And Analysts Lifted Their Price Target To US$52.6010 months ago | Simply Wall St
ShockWave Medical, Inc. Just Reported Earnings, And Analysts Cut Their Target PriceValuation
Is ShockWave Medical undervalued compared to its fair value and its price relative to the market?
10.01x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate SWAV's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate SWAV's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: SWAV is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.
PE vs Market: SWAV is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate SWAV's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: SWAV is overvalued based on its PB Ratio (10x) compared to the US Medical Equipment industry average (3.9x).
Next Steps
Future Growth
How is ShockWave Medical forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
33.7%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SWAV is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: SWAV is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: SWAV is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: SWAV's revenue (45.1% per year) is forecast to grow faster than the US market (9.7% per year).
High Growth Revenue: SWAV's revenue (45.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: SWAV is forecast to be unprofitable in 3 years.
Next Steps
Past Performance
How has ShockWave Medical performed over the past 5 years?
-44.1%
Last years earnings growth
Earnings and Revenue History
Quality Earnings: SWAV is currently unprofitable.
Growing Profit Margin: SWAV is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if SWAV's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare SWAV's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SWAV is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-0.2%).
Return on Equity
High ROE: SWAV has a negative Return on Equity (-26.32%), as it is currently unprofitable.
Next Steps
Financial Health
How is ShockWave Medical's financial position?
Financial Position Analysis
Short Term Liabilities: SWAV's short term assets ($264.3M) exceed its short term liabilities ($17.7M).
Long Term Liabilities: SWAV's short term assets ($264.3M) exceed its long term liabilities ($24.2M).
Debt to Equity History and Analysis
Debt Level: SWAV's debt to equity ratio (6.6%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if SWAV's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: SWAV has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: SWAV has sufficient cash runway for 2.3 years if free cash flow continues to reduce at historical rates of 31.8% each year.
Next Steps
Dividend
What is ShockWave Medical current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate SWAV's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate SWAV's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if SWAV's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SWAV's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of SWAV's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
2.8yrs
Average management tenure
CEO
Doug Godshall (55 yo)
3.33yrs
Tenure
US$2,208,317
Compensation
Mr. Douglas E. Godshall, also known as Doug, M.B.A., has been the Chief Executive Officer and President of Shockwave Medical, Inc. since May 10, 2017. Mr. Godshall has been an Executive Director at HeartWa ...
CEO Compensation Analysis
Compensation vs Market: Doug's total compensation ($USD2.21M) is below average for companies of similar size in the US market ($USD5.70M).
Compensation vs Earnings: Doug's compensation has increased whilst the company is unprofitable.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 3.33yrs | US$2.21m | 0.29% $ 7.1m | |
| CFO & Secretary | 4.42yrs | US$1.24m | 0.11% $ 2.7m | |
| Chief Commercial Officer | 1.83yrs | US$658.55k | 0.17% $ 4.2m | |
| Founder and Senior Advisor | 11.67yrs | no data | no data | |
| Co-Founder and Technical Advisor | 11.67yrs | no data | no data | |
| Vice President of Operations | 1.83yrs | no data | no data | |
| Head of Investor Relations | 0.17yr | no data | no data | |
| General Counsel & Secretary | 1.25yrs | no data | no data | |
| Vice President of Sales | 3.33yrs | no data | no data | |
| Vice President of Marketing | 4.17yrs | no data | no data | |
| Director of Human Resources | 2.25yrs | no data | no data | |
| Chief Medical Officer | 1.33yrs | no data | no data |
2.8yrs
Average Tenure
55.5yo
Average Age
Experienced Management: SWAV's management team is considered experienced (2.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 3.33yrs | US$2.21m | 0.29% $ 7.1m | |
| Independent Director | 7.17yrs | US$185.25k | 0.0079% $ 195.3k | |
| Independent Director | 9.67yrs | US$185.00k | 0.82% $ 20.2m | |
| Independent Chairman of the Board | 1.67yrs | US$161.15k | 0.0079% $ 195.3k | |
| Independent Director | 1.67yrs | US$122.42k | 0.0079% $ 195.3k | |
| Director | 0.17yr | no data | no data | |
| Independent Director | 5.33yrs | US$189.17k | 0.0079% $ 195.3k | |
| Independent Director | 7.67yrs | US$188.33k | 0.34% $ 8.3m |
4.3yrs
Average Tenure
54.5yo
Average Age
Experienced Board: SWAV's board of directors are considered experienced (4.3 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 21.3%.
Top Shareholders
Company Information
ShockWave Medical, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: ShockWave Medical, Inc.
- Ticker: SWAV
- Exchange: NasdaqGS
- Founded: 2009
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$2.460b
- Shares outstanding: 34.00m
- Website: https://www.shockwavemedical.com
Number of Employees
Location
- ShockWave Medical, Inc.
- 5403 Betsy Ross Drive
- Santa Clara
- California
- 95054
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| SWAV | NasdaqGS (Nasdaq Global Select) | Yes | Common Stock | US | USD | Mar 2019 |
| 36M | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Mar 2019 |
Biography
ShockWave Medical, Inc., a medical device company, develops and commercializes intravascular lithotripsy technology to treat calcified plaque in patients with peripheral vascular, coronary vascular, and he ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/09/19 06:41 |
| End of Day Share Price | 2020/09/18 00:00 |
| Earnings | 2020/06/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.